Current Partnering

Bristol-Myers Squibb Company and Tsinghua University of Beijing,  announced the formation of a multi-year strategic partnership Read the full story

Furiex Pharmaceuticals and Menarini Group announced that they have entered into a license agreement by which Furiex will license to Menarini rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East Read the full story

In introducing biotech guru G. Steven Burrill today, Illinois BIO (iBIO) president David Miller likened the speaker to the Michael Jordan of biotechnology. “There will never be the next Steven Burrill,” he said. “At a critical time in biotech’s development, he was there.” Read the full story

GlaxoSmithKline will need to sweeten its $13 per share bid for Human Genome Sciences to about $15 per share to win over its top investors and get a deal done, according to a Reuters survey of analysts on Wednesday Read the full story

Germany’s largest drugmaker Bayer is considering the sale of its blood glucose meters business as it offers few synergies with its other healthcare activities Read the full story

GlaxoSmithKline announced that it will not participate in Human Genome Sciences strategic alternatives review process and will instead commence a tender offer this week to acquire all of the outstanding shares of HGS for US$13.00 per share in cash Read the full story

Santen Pharmaceuticals negotiated co-promotion rights to Regeneron Pharmaceuticals and Bayer HealthCare’s Eylea (aflibercept; VEGF Trap-Eye) injection in Japan Read the full story

Coherus BioSciences and Daiichi Sankyo announced the execution of an exclusive agreement to develop and commercialize biosimilar forms of etanercept and rituximab in certain Asian countries including Japan Read the full story

For four years Chris Viehbacher has been bracing himself for a nasty turn Read the full story

Novartis is buying specialty dermatology generics firm Fougera Pharmaceuticals for $1.525 billion in cash Read the full story